Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.

Acta clinica Belgica - 1 Jun 2023

De Ryck Lore, Delanghe Sigurd, Jacobs Celine, Fadaei Sharareh, Brochez Lieve, Saerens Michael

Abstract excerpt

INTRODUCTION: The introduction of BRAF/MEK inhibitors has significantly improved overall survival of patients with BRAF V600-mutant advanced or metastatic melanoma. Most patients treated with BRAF/MEK inhibitors will experience adverse events during the course of their treatment. Kidney impairment, however, was rarely reported in the pivotal trials. To date, there are only three cases of biopsy-proven acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Nephritis, Interstitial

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Renal Insufficiency

Share to Skin Neoplasms

Source

Identifiers

PMID: 35996969
DOI: 10.1080/17843286.2022.2114684

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.PMID 35996969Read ↗

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib-A case report.Semantic proximity Read ↗

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.Semantic proximity Read ↗

Clinical Features Associated with Immune Checkpoint Inhibitor Nephritis: A Single-Center Clinical Case SeriesSemantic proximity Read ↗

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.Semantic proximity Read ↗

Electrolyte Disorders Induced by Multikinase Inhibitors Therapy for Renal Cell Carcinoma：A Large-Scale Pharmacovigilance AnalysisSemantic proximity Read ↗

PD-1/PD-L1 Inhibitor-Related Cystitis: Clinical Features, Diagnostic Exclusion, and Outcomes in an Eight-Patient Case Series with a Targeted Literature ReviewSemantic proximity Read ↗

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Next-Generation Bruton’s tyrosine kinase Inhibitors plus Rituximab for Chronic Lymphocytic Leukemia-associated Membranoproliferative Glomerulonephritis: A Case ReportSemantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.Semantic proximity Read ↗

Efficacy and safety of a triple combination of glucocorticoids, tofacitinib and calcineurin inhibitors in anti-MDA5 positive dermatomyositisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.